Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials - PubMed (original) (raw)
Clinical Trial
. 2005 Apr;141(4):467-73.
doi: 10.1001/archderm.141.4.467.
Affiliations
- PMID: 15837864
- DOI: 10.1001/archderm.141.4.467
Clinical Trial
Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials
Neil Korman et al. Arch Dermatol. 2005 Apr.
Abstract
Objective: To evaluate the efficacy and safety of 5% imiquimod cream compared with vehicle in the treatment of actinic keratosis (AK).
Design: Two phase 3 randomized, double-blind, parallel-group, vehicle-controlled studies.
Setting: Twenty-six ambulatory care offices, including dermatologists in private practice or research centers.
Patients: Four hundred ninety-two patients, 18 years and older, with 4 to 8 AK lesions in a 25-cm(2) treatment area on the face or the balding scalp were randomized; an additional 162 patients underwent screening but were ineligible.
Interventions: Patients applied 5% imiquimod (Aldara) or vehicle cream to the treatment area once daily, 3 times per week, for 16 weeks, followed by an 8-week posttreatment period.
Main outcome measurements: Complete clearance rate (proportion of patients at the 8-week posttreatment visit with no clinically visible AK lesions in the treatment area), partial clearance rate (proportion of patients at the 8-week posttreatment visit with a >/=75% reduction in the number of baseline AK lesions in the treatment area), and frequency and severity of adverse events and local skin reactions were measured.
Results: Complete and partial clearance rates for imiquimod-treated patients (48.3% and 64.0%, respectively) were clinically and statistically significantly higher than for vehicle-treated patients (7.2% and 13.6%, respectively). The median percentage reduction of baseline lesions was 86.6% for the imiquimod-treated group and 14.3% for the vehicle-treated group.
Conclusion: The 5% imiquimod cream dosed 3 times weekly for 16 weeks is safe and effective for the treatment of AK.
Similar articles
- Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Lebwohl M, et al. J Am Acad Dermatol. 2004 May;50(5):714-21. doi: 10.1016/j.jaad.2003.12.010. J Am Acad Dermatol. 2004. PMID: 15097955 Clinical Trial. - Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology.
Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, Lee JH, Fox TL, Alomar A. Szeimies RM, et al. J Am Acad Dermatol. 2004 Oct;51(4):547-55. doi: 10.1016/j.jaad.2004.02.022. J Am Acad Dermatol. 2004. PMID: 15389189 Clinical Trial. - Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N, Smith CC, Kaur M, Goldenberg G. Swanson N, et al. J Drugs Dermatol. 2013 Nov;12(11):1278-82. J Drugs Dermatol. 2013. PMID: 24196337 Clinical Trial. - Imiquimod for actinic keratosis: systematic review and meta-analysis.
Hadley G, Derry S, Moore RA. Hadley G, et al. J Invest Dermatol. 2006 Jun;126(6):1251-5. doi: 10.1038/sj.jid.5700264. J Invest Dermatol. 2006. PMID: 16557235 Review. - Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.
Gupta AK, Davey V, Mcphail H. Gupta AK, et al. J Cutan Med Surg. 2005 Oct;9(5):209-14. doi: 10.1007/s10227-005-0148-6. J Cutan Med Surg. 2005. PMID: 16502198 Review.
Cited by
- Systematic review of randomized controlled trials of topicals for actinic keratosis field therapy.
Patel P, Wang J, Bitterman D, Mineroff J, Austin E, Jagdeo J. Patel P, et al. Arch Dermatol Res. 2024 Mar 18;316(4):108. doi: 10.1007/s00403-024-02839-y. Arch Dermatol Res. 2024. PMID: 38498070 Review. - Digitally Enhanced Methods for the Diagnosis and Monitoring of Treatment Responses in Actinic Keratoses: A New Avenue in Personalized Skin Care.
Soare C, Cozma EC, Celarel AM, Rosca AM, Lupu M, Voiculescu VM. Soare C, et al. Cancers (Basel). 2024 Jan 23;16(3):484. doi: 10.3390/cancers16030484. Cancers (Basel). 2024. PMID: 38339236 Free PMC article. Review. - Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer.
Garcia-Mouronte E, Berna-Rico E, de Nicolas-Ruanes B, Azcarraga-Llobet C, Alonso-Martinez de Salinas L, Bea-Ardebol S. Garcia-Mouronte E, et al. Int J Mol Sci. 2023 Jun 29;24(13):10835. doi: 10.3390/ijms241310835. Int J Mol Sci. 2023. PMID: 37446011 Free PMC article. Review. - Highlights into historical and current immune interventions for cancer.
Cole K, Al-Kadhimi Z, Talmadge JE. Cole K, et al. Int Immunopharmacol. 2023 Apr;117:109882. doi: 10.1016/j.intimp.2023.109882. Epub 2023 Feb 27. Int Immunopharmacol. 2023. PMID: 36848790 Free PMC article. Review. - Treatment of actinic keratosis: a systematic review.
Worley B, Harikumar V, Reynolds K, Dirr MA, Christensen RE, Anvery N, Yi MD, Poon E, Alam M. Worley B, et al. Arch Dermatol Res. 2023 Jul;315(5):1099-1108. doi: 10.1007/s00403-022-02490-5. Epub 2022 Dec 1. Arch Dermatol Res. 2023. PMID: 36454335 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources